Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSLilly's Onswik cuts basal insulin from a daily shot to a weekly one. The QWINT trials show it matches daily insulin on blood sugar and lowers dangerous lows, but only in type 2 diabetes and only as a non-inferior result.
In a six-patient first-in-human trial, an albumin-binding upgrade to the neuroendocrine tumor drug Lutathera made the radioactive peptide linger far longer. The kidneys came through fine, but the bone marrow became the organ that capped the dose.
The same desmopressin dose produces anywhere from a quarter to more than triple the standard factor VIII rise, set by which single F8 missense variant a patient carries. A 1,441-person study maps the fourteenfold spread.
Among 92 million US adults with no FDA-approved reason to be on a GLP-1 drug, prescribing climbed from 0.1 to 1.5 percent in four years. Recipients skewed female, White, privately insured, and often not overweight at all.
A chromogranin A fragment is depleted in Alzheimer's, corticobasal degeneration, and progressive supranuclear palsy brains. Supplementing it cut tau and amyloid pathology in mice by dialing down adrenaline. Cells and mice only, one lab, no human trial.
Lanreotide showed no benefit on directly measured kidney filtration in the LIPS trial. A cheaper creatinine estimate suggested it helped, but the trial's own confirmatory tests did not back that up.
In advanced fatty-liver mice, semaglutide lowered weight and liver-cancer burden but not fibrosis, and pairing it with an investigational antifibrotic (rencofilstat) added no benefit. A null result with a stage-dependent lesson.
A MarketScan claims analysis of 201,229 adults and 1,139 children on GLP-1 drugs for obesity found five distinct patterns of use, from immediate dropout to persistent treatment. Only 30.7% of adults and 20.3% of children stayed on, and the Northeast held on more than the South.
A 14-center registry followed 140 children on teduglutide for short bowel syndrome for three years. Parenteral feeding fell by half and about a third weaned off entirely, but the share of underweight children rose from 2.3% to 12.7%.
A Lilly post hoc analysis says oral orforglipron cut the 10-year predicted risk of diabetes and heart disease. The risk was a model's projection from surrogates the drug already moves, and no real cases were counted.
A Brazilian doping-control lab dosed four volunteers with the experimental triple-agonist and tracked it in both fluids. Plasma held a detectable signal for about 56 days. Urine, the workhorse of sports testing, came up empty every time, which closes off the cheap screen for a drug that has no regulatory approval anywhere.
A pooled analysis of eight trials found GLP-1 drugs added to antipsychotics cut weight by about 15 pounds and moved blood sugar, with semaglutide the standout. The metabolic surrogates fell, the gut paid for it, and the early-death gap the drugs are meant to close went unmeasured.
LL-37, the antimicrobial peptide human cells make to kill bacteria, cut viability, blood-vessel growth, and lung spread in gastric cancer cells and mice by shutting the NF-kB/IL-6 switch. The catch: the same peptide is reported to feed other cancers, and this is cells and mice only.
A trial won tirzepatide a label for treating obstructive sleep apnea. But a UK cohort of 206,000 obese diabetics found GLP-1 starters developed new apnea at the same rate as a weight-neutral comparator (hazard ratio 1.07). Treating is not the same as preventing.
A 45-expert Delphi panel in World Psychiatry set the first structured rules for GLP-1 weight-loss drugs and eating disorders: screen everyone first, generally avoid the drugs in active anorexia or bulimia, and offer psychotherapy alongside. The catch is that the guidance is formalized expert opinion, not evidence, because the studies to test it do not exist yet.